SCHEMBL4034107

SCHEMBL4034107

O=C(Nc1ccc(-c2n[nH]c(=S)o2)cc1)c1ccccc1F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.70
KMT2A Q03164 5/20 0.70
GFER P55789 1/20 0.59
MAPT P10636 4/20 0.57
RAB9A P51151 4/20 0.57
MPO P05164 1/20 0.57
TDP1 Q9NUW8 2/20 0.57
LMNA P02545 1/20 0.53
KDM4E B2RXH2 4/20 0.53
ALDH1A1 P00352 4/20 0.53
HPGD P15428 3/20 0.53
HSD17B10 Q99714 2/20 0.53
TP53 P04637 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.52
NPC1 O15118 2/20 0.52
HTT P42858 2/20 0.51
RXFP1 Q9HBX9 3/20 0.50
PPARG P37231 1/20 0.50
NCOA2 Q15596 1/20 0.50
NCOA1 Q15788 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032812 0.85 RAB9A (0.54) MEN1KMT2AMAPTRAB9ATDP1
SCHEMBL4238963 0.83 MEN1 (1.00) MEN1KMT2AGFERRAB9AMPO
SCHEMBL4239227 0.82 NPC1 (0.51) MEN1KMT2AMAPTRAB9ATDP1
SCHEMBL4251628 0.81 CHRNA7 (0.53) MEN1KMT2AGFERMAPTRAB9A
SCHEMBL4242129 0.81 CHRNA7 (0.52) MEN1KMT2AMAPTRAB9ATDP1
SCHEMBL4250930 0.80 KMT2A (0.54) MEN1KMT2AMAPTRAB9AMPO
SCHEMBL24473959 0.79 SMO (0.72) MEN1KMT2AMAPTRAB9ATDP1
SCHEMBL30587154 0.79 SMO (0.72) MEN1KMT2AMAPTRAB9ATDP1
SCHEMBL13878308 0.76 MEN1 (0.60) MEN1KMT2AMAPTRAB9ATDP1
SCHEMBL20522049 0.73 LCLAT1 (0.80) MAPTKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-04-23 US disclosed
EP-2021331-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-02-11 EP disclosed
WO-2007138033-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105217-A1 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA2 MEN1 4763/4885KMT2A 2842/4885GFER 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.